Ireland
--:--IST
Active, not recruiting Not applicable

Implant Placement Depth and Peri-Implant Tissue Outcomes

NCT07535528 · tracked via the Priya Life Science Spain tracker
Phase
Not applicable
Started
2026-05-15
Last updated
2026-07-13

Condition(s) studied

Dental Implant PlacementSoft Tissue Management in Subcrestal Dental ImplantsMarginal Bone Loss

Investigational drug(s) / intervention(s)

Subcrestal Implant Placement with Transmucosal Abutment and One Abutment-One Time Protocol

Subcrestal Implant Placement with Transmucosal Abutment and One Abutment-One Time Protocol: Participants will receive bone-level dental implants placed subcrestally at either -2 mm or -4 mm below the bone crest in healed posterior sites of the maxilla or mandible, according to randomization. Implant placement will follow the manufacturer's drilling protocol, achieving a final insertion torque of at least 35 Ncm. A transmucosal abutment will be connected at the time of surgery, with height selected based on implant placement depth (2-3 mm for -2 mm placement and 4-5 mm for -4 mm placement). The abutment will be tightened to a final torque of at least 30 Ncm following a one abutment-one time protocol.

Study summary

The primary aim of this randomized clinical trial is to evaluate the influence of subcrestal implant placement depth (-2 mm vs -4 mm) on peri-implant marginal bone level changes, including marginal bone loss and bone remodeling. Secondary outcomes include implant success, peri-implant probing depth (PPD), and bleeding on probing (BoP).

Partially edentulous patients requiring fixed implant-supported prosthetic rehabilitation with two implants in posterior maxillary or mandibular regions will be included. Implants will be placed subcrestally at either -2 mm or -4 mm from the bone crest, following a submerged healing protocol. Allocation to insertion depth will be randomized. Marginal bone level changes will be assessed using standardized periapical radiographs at second-stage surgery, prosthesis placement, and at 1, 3, 6, and 12 months after functional loading. PPD and BoP will be recorded at the same time points.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Patients ≥18 years old with partial edentulism. * Need for rehabilitation with fixed implant-supported prostheses in posterior regions. * Availability of minimum bone height for implants ≥6 mm in length. * Minimum bone width without the need for guided bone regeneration. * Supracrestal soft tissue thickness ≥2 mm. * Non-smokers or smokers of ≤10 cigarettes/day. * Plaque index and bleeding on probing \<20%. * Probing depth ≤3 mm. * Signed informed consent. Exclusion Criteria: * Systemic diseases contraindicating implant surgery. * Treatment with intravenous bisphosphonates. * Head and neck radiotherapy. * Uncontrolled diabetes. * Pregnancy or breastfeeding. * Alcohol or drug use. * Psychiatric disorders. * Need for bone regeneration procedures. * Inability to complete follow-up. * Implant failure during the study period.

Primary outcome measure(s)

  • Changes in peri-implant marginal bone level (mm) — From abutment placement (baseline time [TB]), 1 month post (T1), and at 3 (T3) (prosthetic loading) , 6 (T6), and 12 (T12) months after definitive prosthesis placement.
    Parallelized periapical radiographs will be obtained and a calibrated digital tool will be used to determine the vertical distance from the implant-abutment junction to the most coronal bone-to-implant contact on the mesial and distal sides. Unit of measure: Milimeters (mm)

Trial sites (1)

FacilityCityRegionStatus
University of Valencia Valencia Spain
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07535528 on ClinicalTrials.gov ↗ ← All trials in Spain